Newsoara BioPharma Co., Ltd. and vTv Therapeutics LLC have expanded their strategic collaboration, with Newsoara securing global rights to HPP737, a novel phosphodiesterase-4 (PDE4) inhibitor in development for psoriasis. The expanded agreement, valued at up to USD 135 million including a USD 20 million upfront payment, builds on their 2018 Asia-Pacific partnership and positions Newsoara to commercialize the anti-inflammatory therapy worldwide.
PDE4 Competitive Landscape:Apremilast (Amgen) first-in-class but limited efficacy; deucravacitinib (BMS) TYK2 inhibitor sets higher efficacy bar; HPP737 requires superior clinical data for differentiation
Newsoara Global Ambition: Expansion from regional to global rights reflects China biotech maturation and capital markets support for international commercialization
Development & Commercial Outlook
Phase
Activity
Timeline
Current
Global rights transition; regulatory strategy alignment
Q1 2026
Clinical
Phase I/II psoriasis trial initiation
2026-2027
Expansion
Proof-of-concept in psoriatic arthritis, atopic dermatitis
2027-2028
Global Partnership
US/EU co-development or licensing discussions
Data-dependent
Commercial
China launch (retained rights); ex-China partnership or self-commercialization
2029+
Forward‑Looking Statements This brief contains forward‑looking statements regarding HPP737 clinical development timelines, psoriasis market penetration, and Newsoara BioPharma’s global commercialization strategy. Actual results may differ due to Phase I/II efficacy outcomes, competitive dynamics with apremilast and deucravacitinib, and partnership negotiation results for US/EU markets.-Fineline Info & Tech
